REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

All Contacts
Dominic D'Agostino
Influencer

Dominic D'Agostino

About

NASA Extreme Environment Mission Operations, or NEEMO, is a NASA analog mission that sends groups of astronauts, engineers and scientists to live in the Aquarius underwater laboratory, the world's only undersea research station, for up to three weeks at a time in preparation for future space exploration. Aquarius is an underwater habitat 3.5 miles (5.6 km) off Key Largo, Florida, in the Florida Keys National Marine Sanctuary. It is deployed on the ocean floor next to deep coral reefs 62 feet (19 m) below the surface. NASA has used it since 2001 for a series of space exploration simulation missions, usually lasting 7 to 14 days, with space research mainly conducted by international astronauts. The mission had cost about 500 million U.S. dollars. The crew members are called aquanauts (as they live underwater at depth pressure for a period equal to or greater than 24 continuous hours without returning to the surface), and they perform EVAs in the underwater environment. A technique known as saturation diving allows the aquanauts to live and work underwater for days or weeks at a time. After twenty four hours underwater at any depth, the human body becomes saturated with dissolved gas. With saturation diving, divers can accurately predict exactly how much time they need to decompress before returning to the surface. This information limits the risk of decompression sickness. By living in the Aquarius habitat and working at the same depth on the ocean floor, NEEMO crews are able to remain underwater for the duration of their mission. For NASA, the Aquarius habitat and its surroundings provide a convincing analog for space exploration. Much like space, the undersea world is a hostile, alien place for humans to live. NEEMO crew members experience some of the same challenges there that they would on a distant asteroid, planet (i.e. Mars) or Moon. During NEEMO missions, the aquanauts are able to simulate living on a spacecraft and test spacewalk techniques for future space m